Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSmith & Nephew Regulatory News (SN.)

Share Price Information for Smith & Nephew (SN.)

Share Price is delayed by 15 minutes
Get Live Data
1,138.50    -7.50 (-0.65%)
Bid:
1,143.00
Ask:
1,143.50
Spread: 0.50 (0.044%)
Market Cap: £9.63b
SN. Live PriceLast checked at - London Stock Exchange

Intraday Smith & Nephew Share Chart

Acquisition

5 Jan 2016 07:00

RNS Number : 7712K
Smith & Nephew Plc
05 January 2016
 

 

 

 

Smith & Nephew completes acquisition of surgical robotics business Blue Belt Technologies

 

5 January 2016

 

 

Smith & Nephew (LSE:SN, NYSE:SNN), the global medical technology business, announces it has completed the acquisition of Blue Belt Holdings, Inc. ("Blue Belt Technologies"), securing a leading position in the fast-growing area of orthopaedic robotics-assisted surgery.

 

Blue Belt Technologies' Navio surgical system currently provides robotics-assistance in unicondylar or partial knee replacement surgery through CT-free navigation software and a unique hand-held, robotic bone-shaping device. Navio and Smith & Nephew's partial knee implant portfolio form a strong combined business from which to accelerate growth in this attractive area of surgery. Additionally, the Group intends to expand the Navio platform into total knee, bi-cruciate retaining knee and revision knee implants, delivering significant further upside.

 

Enquiries

 

InvestorsIngeborg ØieSmith & Nephew

 +44 (0) 20 7960 2285

 

Financial MediaCharles ReynoldsSmith & Nephew

+44 (0) 20 7401 7646

 

Ben Atwell / Matthew ColeFTI Strategic Consulting

 

+44 (0) 20 3727 1000

 

Trade Media

Joe Metzger

Smith & Nephew

 

 

+1 (978) 749-1330

 

About Smith & Nephew

Smith & Nephew is a global medical technology business dedicated to helping healthcare professionals improve people's lives. With leadership positions in Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine and Trauma & Extremities, Smith & Nephew has around 14,000 employees and a presence in more than 100 countries. Annual sales in 2014 were more than $4.6 billion. Smith & Nephew is a member of the FTSE100 (LSE:SN, NYSE:SNN).

 

For more information about Smith & Nephew, please visit our corporate website www.smith-nephew.com, follow @SmithNephewplc on Twitter or visit SmithNephewplc on Facebook.com

 

Forward-looking Statements

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew's expectations.

 

◊Trademark of Smith & Nephew. Certain marks registered US Patent and Trademark Office.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ACQEAKFLEEDKEFF
Date   Source Headline
1st Jun 20165:47 pmRNSTransaction in Own Shares
1st Jun 20162:22 pmRNSTotal Voting Rights
31st May 20165:28 pmRNSTransaction in Own Shares
27th May 20163:11 pmRNSAdditional Listing
26th May 20165:20 pmRNSTransaction in Own Shares
25th May 20165:35 pmRNSTransaction in Own Shares
24th May 20165:22 pmRNSTransaction in Own Shares
19th May 20165:23 pmRNSDirector/PDMR Shareholding
18th May 20164:56 pmRNSDirector/PDMR Shareholding
18th May 20161:00 pmRNSDivestment and share buy-back
12th May 201611:38 amRNSDirector/PDMR Shareholding
5th May 20167:00 amRNSSmith & Nephew 2016 First Quarter Trading Report
3rd May 20161:33 pmRNSTotal Voting Rights
27th Apr 20165:09 pmRNSDividend Declaration
26th Apr 20165:35 pmRNSDirector Declaration
21st Apr 20163:59 pmRNSNotice of Results
14th Apr 20165:14 pmRNSResult of AGM
6th Apr 20164:37 pmRNSDirector/PDMR Shareholding
1st Apr 201611:52 amRNSTotal Voting Rights
10th Mar 20165:31 pmRNSDirector/PDMR Shareholding
8th Mar 20164:14 pmRNSDirector/PDMR Shareholding
4th Mar 201612:46 pmRNSAnnual Financial Report
1st Mar 201611:03 amRNSTotal Voting Rights
22nd Feb 20164:10 pmRNSTransaction in Own Shares
19th Feb 20165:05 pmRNSTransaction in Own Shares
18th Feb 20165:25 pmRNSTransaction in Own Shares
16th Feb 20165:42 pmRNSDirector/PDMR Shareholding
15th Feb 20165:27 pmRNSTransaction in Own Shares
12th Feb 20164:12 pmRNSDirector/PDMR Shareholding
11th Feb 20165:29 pmRNSTransaction in Own Shares
10th Feb 20166:12 pmRNSTransaction in Own Shares
9th Feb 20165:40 pmRNSTransaction in Own Shares
5th Feb 20165:46 pmRNSDirector/PDMR Shareholding
4th Feb 20165:39 pmRNSDirector/PDMR Shareholding
4th Feb 20167:00 amRNSFinal Results
1st Feb 20162:02 pmRNSBlocklisting Interim Review
1st Feb 201612:52 pmRNSTotal Voting Rights
1st Feb 20167:00 amRNSStatement regarding Olivier Bohuon
21st Jan 20169:00 amRNSDirector Declaration
11th Jan 20167:00 amRNSNotice of Results
8th Jan 20163:36 pmRNSDirector/PDMR Shareholding
5th Jan 20167:00 amRNSAcquisition
4th Jan 20163:40 pmRNSTotal Voting Rights
16th Dec 20154:21 pmRNSDirector/PDMR Shareholding
8th Dec 20155:25 pmRNSTransaction in Own Shares
1st Dec 20152:20 pmRNSTotal Voting Rights
24th Nov 20155:45 pmRNSTransaction in Own Shares
23rd Nov 20155:38 pmRNSTransaction in Own Shares
19th Nov 20155:39 pmRNSTransaction in Own Shares
18th Nov 20155:41 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.